Disclosed are alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester used in compositions and methods for inhibiting corrosion. The alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester are reaction products of an alkyl lactone and an amine, and an alkyl lactone and an alcohol, respectively.

Disclosed are alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester used in compositions and methods for inhibiting corrosion. The alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester are reaction products of an alkyl lactone and an amine, and an alkyl lactone and an alcohol, respectively.

Amidoamine-based gemini surfactants having dual chains connected via an alkyl linker. Each chain contains a quaternary ammonium head group and an ethoxylated alkyl tail. Properties of the surfactant including thermal stability, critical micelle concentration, and foam stability are specified. A method of recovering oil from a reservoir using an aqueous composition that contains the surfactant and a polymer (e.g. AM-AMPS) is also provided. This method is particularly effective for oil recovery in reservoirs of high temperature and/or high salinity.

Amidoamine-based gemini surfactants having dual chains connected via an alkyl linker. Each chain contains a quaternary ammonium head group and an ethoxylated alkyl tail. Properties of the surfactant including thermal stability, critical micelle concentration, and foam stability are specified. A method of recovering oil from a reservoir using an aqueous composition that contains the surfactant and a polymer (e.g. AM-AMPS) is also provided. This method is particularly effective for oil recovery in reservoirs of high temperature and/or high salinity.

Disclosed are alkyl lactone-derived hydroxyamides and alkyl lactone-derived hydroxyesters used in compositions and methods for inhibiting natural gas hydrate agglomerates. The alkyl lactone-derived hydroxyamides and alkyl lactone-derived hydroxyesters are reaction products of an alkyl lactone and an amine, and an alkyl lactone and an alcohol, respectively.

Methods of controlling clay swelling and stabilizing subterranean geological formations containing swellable clays (e.g., montmorillonite, bentonite) are described. The methods involve treating the swellable clays with a composition containing an amidoamine-based gemini surfactant. The gemini surfactant has dual chains connected via an alkylene linker, whereby each chain contains a quaternary ammonium head group and an ethoxylated alkyl tail. As examined by linear swelling and free swelling tests, use of the gemini surfactant is effective in reducing swelling of the clays.

Methods of controlling clay swelling and stabilizing subterranean geological formations containing swellable clays (e.g., montmorillonite, bentonite) are described. The methods involve treating the swellable clays with a composition containing an amidoamine-based gemini surfactant. The gemini surfactant has dual chains connected via an alkylene linker, whereby each chain contains a quaternary ammonium head group and an ethoxylated alkyl tail. As examined by linear swelling and free swelling tests, use of the gemini surfactant is effective in reducing swelling of the clays.

Compounds are provided having one of the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

##STR00001##

The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC.sub.50 values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.

The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC.sub.50 values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.